Michelle Francis

Market estimates were developed using a bottom-up market sizing approach, beginning with Singapore's diagnosed Type 2 diabetes population and narrowing down to the eligible treatment and annual treated patient populations. The 2024 market size was calculated using the estimated annual treatment population, an average monthly treatment cost, and validation against the PwC GLP-1 therapeutic distribution referenced in the presentation. Forecast values for 2025–2028 are based on assumptions regarding gradual treatment adoption, increasing physician acceptance, and market maturity as presented in the source material. Competitive analysis and estimated market shares are derived from the products currently available in Singapore and the competitive outlook outlined in the presentation. The report relies on publicly available secondary sources cited in the presentation, including the International Diabetes Federation (IDF), Singapore Ministry of Health (MOH), PwC, Worldometer, and National University of Singapore (NUS). Market share, treatment eligibility, adoption rates, and pricing assumptions are estimates intended for analytical purposes and should not be interpreted as official commercial data. All calculations and conclusions are based on the information provided in the presentation and should be independently validated before being used for strategic or commercial decision-making.